MedKoo Cat#: 412749 | Name: Pirmagrel

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pirmagrel is a selective antithrombotic agent

Chemical Structure

Pirmagrel
Pirmagrel
CAS#85691-74-3

Theoretical Analysis

MedKoo Cat#: 412749

Name: Pirmagrel

CAS#: 85691-74-3

Chemical Formula: C13H16N2O2

Exact Mass: 232.1212

Molecular Weight: 232.28

Elemental Analysis: C, 67.22; H, 6.94; N, 12.06; O, 13.78

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Pirmagrel; CGS13080; CGS-13080; CGS 13080
IUPAC/Chemical Name
Imidazo(1,5-a)pyridine-5-hexanoic acid
InChi Key
LIFOFTJHFFTNRV-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H16N2O2/c16-13(17)8-3-1-2-5-11-6-4-7-12-9-14-10-15(11)12/h4,6-7,9-10H,1-3,5,8H2,(H,16,17)
SMILES Code
O=C(O)CCCCCC1=CC=CC2=CN=CN12
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 232.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ding ZQ, Rowe J, Ng B, Sinosich MJ, Gallery ED. Modulation of prostacyclin and thromboxane secretion by cytotrophoblasts from normal and pre-eclamptic human pregnancies. Placenta. 2002 Sep-Oct;23(8-9):594-9. doi: 10.1053/plac.2002.0851. PMID: 12361679. 2: Brännström K, Arendshorst WJ. Thromboxane A2 contributes to the enhanced tubuloglomerular feedback activity in young SHR. Am J Physiol. 1999 May;276(5):F758-66. doi: 10.1152/ajprenal.1999.276.5.F758. PMID: 10330058. 3: Heylen L, De Clerck F, Somers Y, Leysen JE. Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist. Blood Coagul Fibrinolysis. 1991 Oct;2(5):617-21. doi: 10.1097/00001721-199110000-00005. PMID: 1838285. 4: Rowe J, Campbell S, Gallery ED. Effects of hypoxia on regulation of prostanoid production in decidual endothelial cells in normal and preeclamptic pregnancy. J Soc Gynecol Investig. 2000 Mar-Apr;7(2):118-24. PMID: 10785612. 5: Chouinard ML, Martin LL, Coffman T, Hamilton BH, Linberg LF, Pamidi A, Simke JP, Rakhit A. Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients. Clin Pharmacol Ther. 1992 Dec;52(6):597-604. doi: 10.1038/clpt.1992.197. PMID: 1458769. 6: Fiddler GI, Lumley P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation. 1990 Jan;81(1 Suppl):I69-78; discussion I79-80. PMID: 2136820. 7: Puri N, Zhang F, Monu SR, Sodhi K, Bellner L, Lamon BD, Zhang Y, Abraham NG, Nasjletti A. Antioxidants condition pleiotropic vascular responses to exogenous H(2)O(2): role of modulation of vascular TP receptors and the heme oxygenase system. Antioxid Redox Signal. 2013 Feb 10;18(5):471-80. doi: 10.1089/ars.2012.4587. Epub 2012 Sep 28. PMID: 22867102; PMCID: PMC3545357. 8: Huang A, Sun D, Koller A. Endothelial dysfunction augments myogenic arteriolar constriction in hypertension. Hypertension. 1993 Dec;22(6):913-21. doi: 10.1161/01.hyp.22.6.913. PMID: 8244524. 9: Ku EC, McPherson SE, Signor C, Chertock H, Cash WD. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models. Biochem Biophys Res Commun. 1983 May 16;112(3):899-906. doi: 10.1016/0006-291x(83)91702-3. PMID: 6687803. 10: Shebuski RJ, Storer BL, Fujita T. Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. Thromb Res. 1988 Dec 1;52(5):381-92. doi: 10.1016/0049-3848(88)90022-9. PMID: 3146820.